An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes

BMC Endocrine Disorders

Research Article

María Cepeda¹  Fernando Gomez-Peralta²  Elvira Alcarria²  Maria Jesús Garcia-Llorente²  Cristina Albornos²  Concepción Moreno²  Cristina Abreu²  Jose Carlos Castro²  Margarita Cruz-Bravo²  Francisca Almodóvar³ 

[1] Servicio de Medicina Interna, Hospital General de Segovia, Segovia, Spain;Unidad de Endocrinología y Nutrición, Hospital General de Segovia, C/ Miguel Servet s/n, 40002, Segovia, Spain;Unidad de Endocrinología y Nutrición, Hospital de Alcorcón, Madrid, Spain;

关键词: Excessive daytime sleepiness;    Abnormal sleep patterns;    Obstructive sleep apnoea;    Type 2 diabetes;    Obesity;    Liraglutide;    Glucagon-like peptide-1;   

DOI  :  10.1186/s12902-015-0074-6

 received in 2015-05-25, accepted in 2015-11-30,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundThe main purpose of the present study is to evaluate whether treatment with long-acting human glucagon-like peptide-1 liraglutide was associated with an improvement of excessive daytime sleepiness (EDS) in obese subjects with type-2 diabetes.MethodsThis single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m2) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion. Data of the Epworth Sleepiness Scale (ESS), anthropometric parameters, glucose-control and metabolic parameters were collected at liraglutide initiation (baseline) and at months 1 and 3 after liraglutide initiation.ResultsSignificant reductions in ESS score were achieved at months 1 (−1.3 ± 2.8, p < 0.001) and 3 (−1.5 ± 3.0, p < 0.001) after liraglutide introduction. After 3 months of treatment with liraglutide, significant changes in body weight (p < 0.001), BMI (p < 0.001), waist (p < 0.001) and neck circumferences (p < 0.005), HbA1c (p < 0.001), mean blood glucose (p < 0.001), fasting plasma glucose (p < 0.001), triglycerides (p < 0.01) and total cholesterol (p < 0.001) were achieved.ConclusionsAfter 3 months of treatment with liraglutide a significant reduction in EDS was observed in obese subjects with type-2 diabetes. Besides this, significant changes in body weight and metabolic parameters of diabetes control were also accomplished. Further investigation is required to determine whether liraglutide could improve other abnormal sleep patterns and obstructive sleep apnoea.

【 授权许可】

CC BY   
© Gomez-Peralta et al. 2015